Vision loss in glioblastoma: Disease mimicking presumed therapeutic toxicity
Glioblastoma is the most common and lethal form of primary brain cancer. In the recurrent setting, bevacizumab is a common choice for salvage therapy. Loss of vision in patients initially treated with radiation at the time of diagnosis and later treated with bevacizumab at time of recurrence has bee...
Saved in:
| Published in | Neuro-oncology practice Vol. 5; no. 4; pp. 223 - 226 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Oxford University Press
02.11.2018
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Glioblastoma is the most common and lethal form of primary brain cancer. In the recurrent setting, bevacizumab is a common choice for salvage therapy. Loss of vision in patients initially treated with radiation at the time of diagnosis and later treated with bevacizumab at time of recurrence has been reported, and presumed to be a treatment-related optic neuropathy. Strikingly, only 1 case report described a postmortem biopsy to rule out tumor involvement of the optic tracts. We report the first case of recurrent glioblastoma infiltrating the prechiasmatic and chiasmatic optic nerve, which at the time of vision loss was presumed to be secondary to bevacizumab. It is noteworthy that the MRI findings in the previously reported bevacizumab/radiation-induced optic neuropathy cases (without pathology follow-up) are comparable to our patient. |
|---|---|
| AbstractList | Glioblastoma is the most common and lethal form of primary brain cancer. In the recurrent setting, bevacizumab is a common choice for salvage therapy. Loss of vision in patients initially treated with radiation at the time of diagnosis and later treated with bevacizumab at time of recurrence has been reported, and presumed to be a treatment-related optic neuropathy. Strikingly, only 1 case report described a postmortem biopsy to rule out tumor involvement of the optic tracts. We report the first case of recurrent glioblastoma infiltrating the prechiasmatic and chiasmatic optic nerve, which at the time of vision loss was presumed to be secondary to bevacizumab. It is noteworthy that the MRI findings in the previously reported bevacizumab/radiation-induced optic neuropathy cases (without pathology follow-up) are comparable to our patient. Abstract Glioblastoma is the most common and lethal form of primary brain cancer. In the recurrent setting, bevacizumab is a common choice for salvage therapy. Loss of vision in patients initially treated with radiation at the time of diagnosis and later treated with bevacizumab at time of recurrence has been reported, and presumed to be a treatment-related optic neuropathy. Strikingly, only 1 case report described a postmortem biopsy to rule out tumor involvement of the optic tracts. We report the first case of recurrent glioblastoma infiltrating the prechiasmatic and chiasmatic optic nerve, which at the time of vision loss was presumed to be secondary to bevacizumab. It is noteworthy that the MRI findings in the previously reported bevacizumab/radiation-induced optic neuropathy cases (without pathology follow-up) are comparable to our patient. |
| Author | Howard, Steven Salamat, M Shahriar Vo, Kevin B H Robins, H Ian Nguyen, HuyTram N Rowely, Howard |
| AuthorAffiliation | 1 University of Wisconsin – School of Medicine and Public Health 2 Department of Human Oncology, University of Wisconsin – School of Medicine and Public Health 3 Department of Pathology, University of Wisconsin – School of Medicine and Public Health 4 Department of Medicine, Neurology, Human Oncology - University of Wisconsin – School of Medicine and Public Health |
| AuthorAffiliation_xml | – name: 3 Department of Pathology, University of Wisconsin – School of Medicine and Public Health – name: 1 University of Wisconsin – School of Medicine and Public Health – name: 4 Department of Medicine, Neurology, Human Oncology - University of Wisconsin – School of Medicine and Public Health – name: 2 Department of Human Oncology, University of Wisconsin – School of Medicine and Public Health |
| Author_xml | – sequence: 1 givenname: HuyTram N surname: Nguyen fullname: Nguyen, HuyTram N organization: University of Wisconsin - School of Medicine and Public Health – sequence: 2 givenname: Kevin B H surname: Vo fullname: Vo, Kevin B H organization: University of Wisconsin - School of Medicine and Public Health – sequence: 3 givenname: Steven surname: Howard fullname: Howard, Steven organization: Department of Human Oncology, University of Wisconsin - School of Medicine and Public Health – sequence: 4 givenname: M Shahriar surname: Salamat fullname: Salamat, M Shahriar organization: Department of Pathology, University of Wisconsin - School of Medicine and Public Health – sequence: 5 givenname: Howard surname: Rowely fullname: Rowely, Howard organization: University of Wisconsin - School of Medicine and Public Health – sequence: 6 givenname: H Ian surname: Robins fullname: Robins, H Ian organization: Department of Medicine, Neurology, Human Oncology - University of Wisconsin - School of Medicine and Public Health |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30402261$$D View this record in MEDLINE/PubMed |
| BookMark | eNpVkUtLAzEUhYNUbK3d-AMkSxFq85hkZlwIUp9QcKNuQyZN2-hMMiYZaf-9kdaiq3vhfpxzuOcY9KyzGoBTjC4xKunEunZi2zWi-QEYEMSyMWEF6-33PO-DUQjvCCFMOaZFeQT6FGWIEI4HYPZmgnEW1i4EaCxc1sZVtQzRNfIK3pqgZdCwMY1RH8YuYet16Bo9h3GlvWx1F42C0a2NMnFzAg4Xsg56tJtD8Hp_9zJ9HM-eH56mN7OxonkRx3OCSaVUVWJa8pLMsyKtquIsLwusFcaYMqQkJSXnGckk42zBirwqEGUJk3QIrre6bVelLErb6GUtWm8a6TfCSSP-X6xZiaX7Epwky4wkgfOdgHefnQ5RNCYoXdfSatcFkTCU3GhKMgQXW1T59CKvF3sbjMRPAyI1ILYNJPjsb7A9-vtv-g3lFIU9 |
| CitedBy_id | crossref_primary_10_1016_j_radcr_2023_05_037 |
| Cites_doi | 10.1007/s11060-010-0336-0 10.1212/WNL.0b013e3181c3fd00 10.1016/0360-3016(94)90346-8 10.1186/1756-9966-31-37 10.1016/j.ijrobp.2004.12.009 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2018. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. 2018 |
| Copyright_xml | – notice: The Author(s) 2018. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. 2018 |
| DBID | NPM AAYXX CITATION 7X8 5PM |
| DOI | 10.1093/nop/npx037 |
| DatabaseName | PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
| DatabaseTitleList | PubMed CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 2054-2585 |
| EndPage | 226 |
| ExternalDocumentID | 10_1093_nop_npx037 30402261 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: ; ; ; – fundername: ; ; ; grantid: 4P 30 CA014520 |
| GroupedDBID | 0R~ 4.4 48X 53G 5VS 5WD AABZA AACZT AAOGV AAPQZ AAPXW AARHZ AAUAY AAUQX AAVAP ABDBF ABJNI ABNHQ ABPQP ABPTD ABQLI ABQNK ABWST ABXVV ACGFS ACYHN ADBBV ADGZP ADHZD ADIPN ADQBN ADRTK ADVEK AETBJ AFFZL AFXAL AGINJ AGQXC AGUTN AJEEA ALMA_UNASSIGNED_HOLDINGS AOIJS ATGXG AVWKF BAYMD BCRHZ BEYMZ C45 EBS EJD ENERS FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT H13 HYE KBUDW KOP KSI KSN M49 MHKGH NOMLY NOYVH NPM NU- O9- OAUYM OCZFY ODMLO OJZSN OK1 OPAEJ OVD OWPYF ROX RPM RUSNO TEORI TJX YXANX AASNB AAYXX CITATION 7X8 5PM |
| ID | FETCH-LOGICAL-c378t-d212bccb9139692d48b91cb657981ec111350ca32966424a565f587b8035cb6a3 |
| IEDL.DBID | RPM |
| ISSN | 2054-2577 |
| IngestDate | Tue Sep 17 21:26:34 EDT 2024 Fri Oct 25 08:39:54 EDT 2024 Fri Aug 23 03:52:52 EDT 2024 Wed Oct 16 00:59:21 EDT 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 4 |
| Keywords | Optic neuropathy Glioblastoma Radiation Bevacizumab |
| Language | English |
| License | This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c378t-d212bccb9139692d48b91cb657981ec111350ca32966424a565f587b8035cb6a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://academic.oup.com/nop/article-pdf/5/4/223/29006256/npx037.pdf |
| PMID | 30402261 |
| PQID | 2130803311 |
| PQPubID | 23479 |
| PageCount | 4 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6213942 proquest_miscellaneous_2130803311 crossref_primary_10_1093_nop_npx037 pubmed_primary_30402261 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-11-02 |
| PublicationDateYYYYMMDD | 2018-11-02 |
| PublicationDate_xml | – month: 11 year: 2018 text: 2018-11-02 day: 02 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: US |
| PublicationTitle | Neuro-oncology practice |
| PublicationTitleAlternate | Neurooncol Pract |
| PublicationYear | 2018 |
| Publisher | Oxford University Press |
| Publisher_xml | – name: Oxford University Press |
| References | 7960976 - Int J Radiat Oncol Biol Phys. 1994 Nov 15;30(4):755-63 22538017 - J Exp Clin Cancer Res. 2012 Apr 26;31:37 25032005 - J Adv Pract Oncol. 2013 Jul;4(4):252-6 15990010 - Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1070-7 19949039 - Neurology. 2009 Dec 1;73(22):1924-6 20680396 - J Neurooncol. 2011 May;102(3):485-90 Fu (2019072609011935000_CIT0006) 2013; 4 Sherman (2019072609011935000_CIT0005) 2009; 73 Parsons (2019072609011935000_CIT0001) 1994; 30 Bhandare (2019072609011935000_CIT0002) 2005; 62 Hoang (2019072609011935000_CIT0003) 2012; 31 Kelly (2019072609011935000_CIT0004) 2011; 102 |
| References_xml | – volume: 102 start-page: 485 issue: 3 year: 2011 ident: 2019072609011935000_CIT0004 article-title: Unexpected late radiation neurotoxicity following bevacizumab use: a case series publication-title: J Neurooncol doi: 10.1007/s11060-010-0336-0 contributor: fullname: Kelly – volume: 73 start-page: 1924 issue: 22 year: 2009 ident: 2019072609011935000_CIT0005 article-title: Optic neuropathy in patients with glioblastoma receiving bevacizumab publication-title: Neurology doi: 10.1212/WNL.0b013e3181c3fd00 contributor: fullname: Sherman – volume: 30 start-page: 755 issue: 4 year: 1994 ident: 2019072609011935000_CIT0001 article-title: Radiation optic neuropathy after megavoltage external-beam irradiation: analysis of time-dose factors publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/0360-3016(94)90346-8 contributor: fullname: Parsons – volume: 31 start-page: 37 year: 2012 ident: 2019072609011935000_CIT0003 article-title: Enhancement of radiation response with bevacizumab publication-title: J Exp Clin Cancer Res doi: 10.1186/1756-9966-31-37 contributor: fullname: Hoang – volume: 62 start-page: 1070 issue: 4 year: 2005 ident: 2019072609011935000_CIT0002 article-title: Does altered fractionation influence the risk of radiation-induced optic neuropathy publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2004.12.009 contributor: fullname: Bhandare – volume: 4 start-page: 252 issue: 4 year: 2013 ident: 2019072609011935000_CIT0006 article-title: Two patients with brain tumors who received bevacizumab and radiotherapy: optic neuropathy and quality-of-life issues publication-title: J Adv Pract Oncol contributor: fullname: Fu |
| SSID | ssj0001361389 |
| Score | 2.118018 |
| Snippet | Glioblastoma is the most common and lethal form of primary brain cancer. In the recurrent setting, bevacizumab is a common choice for salvage therapy. Loss of... Abstract Glioblastoma is the most common and lethal form of primary brain cancer. In the recurrent setting, bevacizumab is a common choice for salvage therapy.... |
| SourceID | pubmedcentral proquest crossref pubmed |
| SourceType | Open Access Repository Aggregation Database Index Database |
| StartPage | 223 |
| SubjectTerms | Case Study |
| Title | Vision loss in glioblastoma: Disease mimicking presumed therapeutic toxicity |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/30402261 https://search.proquest.com/docview/2130803311 https://pubmed.ncbi.nlm.nih.gov/PMC6213942 |
| Volume | 5 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3PT4MwFG62nbwYjb_wV2r0yoCWluLNTJfFqPHgzG6kLagkoxBlyf58X2GYTW_eSICGfH3hfa_vve8hdKViGfrKl65O7WmV8oWrwki5MRfcV7Gyml-22uKJT6bh_YzNeoh1vTBN0b5W-dDMi6HJP5rayqrQXlcn5j0_jjgB3hISr4_6YKBrIXpzsEK5Tb7ZoXJAR1wwyaiTJY2pZ8rKM9XSp3b6HoTy4MJ4sOmT_hDN3_WSaw5ovIO2V8wR37RfuIt6mdlDD69Nbziew7o4N_h9npcKCHFdFvIa37bZF1zkRa7tmTi2Za_wN0rxWt8VrstlroGN76Pp-O5lNHFXAxJcTSNRuyn4HaW1stKePCaANlxqxVkUiyDTdoo887WkBGKakIQSyNsbE5ESPmXwmKQHaGBKkx0hHAsVpZlgxJcQw8SBiCQTVs2Pk5CGRDnosoMoqVodjKTNX9MEME1aTB100aGXgJna3IM0Wbn4SmDHgJtSGgQOOmzR_Fmn2wYHRRs4_zxgJbA374BlNFLYK0s4_vebJ2gLKJBougvJKRrUn4vsDGhGrc4bs_oGg7TS4A |
| link.rule.ids | 230,315,730,783,787,888,27938,27939,53806,53808 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NT9wwEB0BPZRLoYKWLf0wKtdsHDtxnN4qKNrCgnoAxC3yeEMbsXFWbVZC_HrGyQbt0lN7i-QkcvzszLNn5g3AIWYm5shNYCf-tAq5DjBOMciUVhwz9JpfPtriQo2u4tOb5GYNkj4Xpg3at1gO3bQauvJXG1s5q2zYx4mFP86PlCDeEotwHV7QeuVqaZPeHq1I5d1vvqwcEZKAJmXaC5NmMnT1LHSzey59_T3azJMRU9GqVfqLaj6PmFwyQSdbcN13vos8uRvOGxzah2e6jv_8ddvwakFK2deu-TWsFW4Hxtdt2jmbUodZ6djPaVkjce2mrswXdtw5dlhVVqX1x-3MR9TSj27CllK6WFPfl5aI_i5cnXy7PBoFi9oLgZWpboIJmTS0Fr1qqMoEAUmXFlWSZjoqrC9Qn3BrpKDtUixiQ7zwNtEpai4Tus3IN7DhalfsAcs0ppNCJ4Ib2h5lkU5Nor1QoBKxjAUO4HM_9vmsk9jIO9e4zAmsvANrAAc9LDmtAO_WMK6o539yGi6ivVJG0QDedjA9vafHdwDpCoBPN3h17dUWgqVV2V7A8O6_n_wEL0eX5-N8_P3ibB82iWnpNolRvIeN5ve8-EBspsGP7dx9BCMX9NM |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NT9wwEB21VKp66Yf6wVJaXNFrNo6dOE5vCLqiLSAOpUK9RB4nQNSNE9GshPrrO042aBdu3CLFiWI_O_PGM34D8BkzE3PkJrCF361CrgOMUwwypRXHDL3ml8-2OFGHZ_H38-R8pdRXn7RvsZq6eT111VWfW9nWNhzzxMLT430liLfEImyLi_AxPKE1y_WKo95vr0jlQ3C-tByRkoAmZjqKk2YydE0buvaGS1-Djxx6MmQqWrdM9-jm3azJFTM0ewG_xw4M2Sd_posOp_bfHW3HB_XwJTxfklO2NzR5BY9K9xqOfvXHz9mcPppVjl3OqwaJc3dNbb6wgyHAw-qqrqzfdmc-s5Z-eAVbOdrFuuamskT438DZ7OvP_cNgWYMhsDLVXVCQaUNr0auHqkwQoHRpUSVppqPS-kL1CbdGCnKbYhEb4ocXiU5Rc5lQMyPfwoZrXLkJLNOYFqVOBDfkJmWRTk2ivWCgErGMBU5gdxz_vB2kNvIhRC5zAiwfAJvApxGanFaCD28YVzaLvzkNGdFfKaNoAu8GqG7fM2I8gXQNxNsGXmV7_Q5B06ttL6HYevCTO_D09GCWH307-fEenhHh0v1ZRrENG931ovxApKbDj_30_Q_YuvdT |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Vision+loss+in+glioblastoma%3A+Disease+mimicking+presumed+therapeutic+toxicity&rft.jtitle=Neuro-oncology+practice&rft.au=Nguyen%2C+HuyTram+N&rft.au=Vo%2C+Kevin+B+H&rft.au=Howard%2C+Steven&rft.au=Salamat%2C+M+Shahriar&rft.date=2018-11-02&rft.pub=Oxford+University+Press&rft.issn=2054-2577&rft.eissn=2054-2585&rft.volume=5&rft.issue=4&rft.spage=223&rft.epage=226&rft_id=info:doi/10.1093%2Fnop%2Fnpx037&rft_id=info%3Apmid%2F30402261&rft.externalDBID=PMC6213942 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2054-2577&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2054-2577&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2054-2577&client=summon |